Journal article · 2026 · Open access

Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer

Yu-Ting Jiang, Guangqi Li, Yuwen Zhou, Ze-Dong Jiang, Yunuo Zhao, Yu Zhang, Xiao-Meng Yin, Shen Li, Huan Tong, Lu-Si Feng, Shiyu Wen, Xueyan Zhou and 17 more

Cell Host & Microbe, 34(11), 2211–2228.e18 · Published 16 October 2026 · DOI 10.1016/j.chom.2026.09.014

Open full textCite this paper

In brief

“Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer” is a 2026 journal article by Yu-Ting Jiang and 28 co-authors, published in Cell Host & Microbe. OpenAlex counts 0 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at Cell Host & Microbe.

Citations
0
References
72
Authors
29

Abstract

Approximately 85% of colorectal cancers (CRCs) are microsatellite stable (MSS) and thus exhibit intrinsic resistance to anti-programmed death-1 (PD-1) therapy. In this study, we demonstrate that oral administration of Akkermansia muciniphila (Akk) suppresses tumorigenesis and reprograms the tumor microenvironment in MSS CRC mouse models. Akk attenuates macrophage efferocytosis through the TLR2/NF-κB pathway, an effect that leads to the accumulation of apoptotic cancer cells, which activates the cGAS-STING pathway and potentiates type I interferon production. This immunostimulatory cascade activates effector CD8 + T cells and enhances the response to anti-PD-1 therapy. We conducted a phase 1 trial (NCT06865521) combining Akk probiotics with PD-1 antibody in patients with metastatic MSS CRC after ≥1 prior line of therapy. The combination therapy was safe and achieved an objective response rate of 19%, with responders exhibiting enhanced antitumor immunity. Our multilevel investigation provides a promising strategy to overcome immunotherapy resistance in MSS CRC through targeted modulation of the gut microbiome.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Jiang, Y.-T., Li, G., Zhou, Y., Jiang, Z.-D., Zhao, Y., Zhang, Y., Yin, X.-M., Li, S., Tong, H., Feng, L.-S., Wen, S., Zhou, X., Ren-wei, L., Wei, J., Qiu, J.-P., Wei, Y., Tan, K.-Q., Zhang, S., Zhou, H.-R., . . . Ma, X.-L. (2026). Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer. Cell Host & Microbe, 34(11), 2211–2228.e18. https://doi.org/10.1016/j.chom.2026.09.014

MLA 9

Jiang, Yu-Ting, et al. “Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer.” Cell Host & Microbe, vol. 34, no. 11, 2026, pp. 2211–2228.e18. https://doi.org/10.1016/j.chom.2026.09.014.

Chicago

Jiang, Yu-Ting, Guangqi Li, Yuwen Zhou, Ze-Dong Jiang, Yunuo Zhao, Yu Zhang, Xiao-Meng Yin, et al. 2026. “Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer.” Cell Host & Microbe 34 (11): 2211–2228.e18. https://doi.org/10.1016/j.chom.2026.09.014.

Harvard

Jiang, Y.-T. et al. (2026) ‘Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer’, Cell Host & Microbe, 34(11), pp. 2211–2228.e18. doi:10.1016/j.chom.2026.09.014.

IEEE

Y.-T. Jiang et al., “Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer,” Cell Host & Microbe, vol. 34, no. 11, pp. 2211–2228.e18, 2026, doi: 10.1016/j.chom.2026.09.014.

BibTeX

@article{jiang2026akkermansia,
  title     = {{Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer}},
  author    = {Jiang, Yu-Ting and Li, Guangqi and Zhou, Yuwen and Jiang, Ze-Dong and Zhao, Yunuo and Zhang, Yu and Yin, Xiao-Meng and Li, Shen and Tong, Huan and Feng, Lu-Si and Wen, Shiyu and Zhou, Xueyan and Ren-wei, LI and Wei, Jingwen and Qiu, Jie-ping and Wei, Yuhao and Tan, Ke-Qin and Zhang, Shengxin and Zhou, Hao-Rui and Yang, Jia-Qing and Bai, Jing and Deng, Qin and Yang, Xinggang and Yang, Xiaoqian and Wang, Yu-Sha and Wei, Xiawei and Qiu, Meng and Huang, Juan and Ma, Xue-Lei},
  journal   = {Cell Host \& Microbe},
  year      = {2026},
  volume    = {34},
  number    = {11},
  pages     = {2211--2228.e18},
  doi       = {10.1016/j.chom.2026.09.014},
  url       = {https://doi.org/10.1016/j.chom.2026.09.014}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers

  • Akkermansia muciniphila
  • microsatellite stable colorectal cancer
  • macrophage efferocytosis
  • anti-PD-1 therapy
  • immunotherapy resistance
  • cGAS-STING pathway
  • type I interferon
  • CD8+ T cells

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Jiang, Y.-T., Li, G., Zhou, Y., Jiang, Z.-D., Zhao, Y., Zhang, Y., Yin, X.-M., Li, S., Tong, H., Feng, L.-S., Wen, S., Zhou, X., Ren-wei, L., Wei, J., Qiu, J.-P., Wei, Y., Tan, K.-Q., Zhang, S., Zhou, H.-R., . . . Ma, X.-L. (2026). Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer. Cell Host & Microbe, 34(11), 2211–2228.e18. https://doi.org/10.1016/j.chom.2026.09.014

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Cell Host & Microbe: sign in and open the full text from this page.

Who wrote this paper?

Yu-Ting Jiang, Guangqi Li, Yuwen Zhou, Ze-Dong Jiang, Yunuo Zhao, Yu Zhang, Xiao-Meng Yin, Shen Li, Huan Tong, Lu-Si Feng, Shiyu Wen, Xueyan Zhou and 17 more.

What is the DOI of this paper?

10.1016/j.chom.2026.09.014, permanently at https://doi.org/10.1016/j.chom.2026.09.014. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.